


VHL Ligand 8

Cat. No.:	HY-133045		
CAS No.:	2701565-76-4		
Molecular Formula:	C ₂₃ H ₂₉ N ₃ O ₆		
Molecular Weight:	443.49		
Target:	Ligands for E3 Ligase		
Pathway:	PROTAC		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (225.48 mM; Need ultrasonic)
 H₂O : 25 mg/mL (56.37 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.2548 mL	11.2742 mL	22.5484 mL
	5 mM	0.4510 mL	2.2548 mL	4.5097 mL
	10 mM	0.2255 mL	1.1274 mL	2.2548 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
 Solubility: 50 mg/mL (112.74 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

VHL Ligand 8 is a VHL ligand. VHL Ligand 8 can be used to synthesize ARD-266 (HY-133020), a highly potent and VHL E3 ligase-based androgen receptor (AR) PROTAC degrader. ARD-266 effectively induces degradation of AR protein in AR-positive LNCaP, VCaP, and 22Rv1 prostate cancer cell lines with DC₅₀ values of 0.2-1 nM^[1].

IC₅₀ & Target

VHL

REFERENCES

[1]. Han X, Zhao L, et al. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. J

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA